Therapeutic strategies to optimize the efficacy of nicotine replacement therapies

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 6, Issue 4, 2009, Pages 272-276

  Berlin, Ivan ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

COPD; Nicotine replacement therapy; Pharmacotherapeutic strategies; Smoking cessation

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; VARENICLINE;

ADD ON THERAPY; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DYSPEPSIA; FATIGUE; FORCED EXPIRATORY VOLUME; HUMAN; LOZENGE; MORTALITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; TABLET FORMULATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BUPROPION; COMBINED MODALITY THERAPY; HUMANS; NICOTINE; NORTRIPTYLINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 70350433690     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550903049116     Document Type: Conference Paper

References (29)

1. CDC. Deaths from Chronic Obstructive Pulmonary Disease. United States, 2000-2005. MMWR 2008; 57:1229-1232.
2. CDC. Annual smoking-attributable mortality, years of potential life lost, and productivity losses.United States, 1997-2001. MMWR 2005; 54:625-628
3. Willemse BWM, Postma DS, Timens W, Ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Resp J. 2005; 23:464-476
4. Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, Burns DM, Prescott E, Vestbo J. COPD-related morbidity and mortality after smoking cessation: Status of the evidence. Eur Resp J 2008; 32:844-853
5. Anthonisen NR, Connett JE,Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166:675-679
6. Murray RP, Connett JE, Rand CS, Pan W, Anthonisen NR. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Prev Med. 2002; 35:314-319
7. U.S. Department of Health and Human Services, Public Health Service. May 2008, Clinical Practice Guideline. Treating Tobacco Use and Dependence: 2008 Update, http://www.surgeongeneral.gov/tobacco/treating tobaccouse08.pdf
8. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation (Review). The Cochrane Library, 2007, Issue 4, http://www.thecochranelibrary.com
9. Tashkin DP, Kanner R, Bailey W, Buist S, Anderson P, Nides MA, Gonzales D, Dozier G, Patel MK, B D Jamerson BD. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial. Lancet 2001; 357:1571-1575
10. Wagena EJ, van der Meer RM, Ostelo RJ, Jacobs JE, van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: Results from a systematic review. Respir Med. 2004; 98:805-815
11. ClinicalTrials.gov. Smoking Cessation in Subjects With Mild-to-Moderate Chronic Obstructive Pulmonary Disease (COPD). ClinicalTrials.govIdentifier: NCT00285012. Accessed on November 24, 2008.
12. Wagena, EJ, Knipschild PG, Huibers MJH, Wouters EFM, van Schayck CP. Efficacy of Bupropion and Nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005; 165:2286-2292
13. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272:1497-1505
14. Tønnesen P, Kim Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130:334-342
15. Wagena EJ, Zeegers MPA, van Schayck CP, Wouters EFM. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Safety 2003; 26:381-403.
16. Jimenez-Ruiz CA, Masa F, Miravitlles M, Gabriel R, Viejo JL, Villasante C, Sobradillo V. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119:1365-1370
17. Centre for Evidence Based Medicine, Oxford Centre for Evidence-based Medicine. Levels of Evidence May 2001, www.cebm.net.
18. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation (Review). The Cochrane Library, 2008, Issue 4, http://www.thecochranelibrary.com
19. Tønnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, Rijcken B, Sawe U. Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13:238-246
20. Shiffman S, Ferguson SG. Nicotine patch therapy prior to quitting smoking: A meta-analysis. Addiction 2008;103:557-563
21. Schuurmans MM, van Diacon AHBX, Bolliger C. Effect of pretreatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: A randomized controlled trial. Addiction 2004; 99:634-640
22. Rose JE, Behm FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 2006; 8:89-101.
23. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New Engl J Med 1999; 340:685-691.
24. Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: Pragmatic randomised controlled trial. BMJ 2008; 336(7655):1223-1227.
25. http://www.pfizer.com/files/products/uspichantix.pdf. Accessed on December 1, 2008.
26. van der Meer RM,Wagena EJ,Ostelo RWJG, Jacobs JE, van Schayck CP. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2001, Issue 1. Art. No.: CD002999.DOI: 10.1002/14651858. CD002999.
27. Murray RP, Nides MA, Istvan JA, Daniels K. Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial. Addict Behav 1998; 23:529-535.
28. Medioni J, Berlin I, Mallet A. Increased risk of relapse after stopping nicotine replacement therapies: A mathematical modelling approach. Addiction. 2005; 100:247-254.
29. ClinicalTrials.gov. Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS). ClinicalTrials.govIdentifier:NCT00235313. Accessed on December 1, 2008.